Ralph V. Boccia, MD
Advertisement
Ralph V. Boccia, MD, is the founder of The Center for Cancer and Blood Disorders and board-certified in medical oncology, hematology and internal medicine.
Articles by Ralph V. Boccia, MD
Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.
Advertisement
Latest Updated Articles
Case Impressions: 66-Year-Old Man With mCSPCDecember 2nd 2020
- AR-Targeted Therapy for mCSPC: Monitoring for Progression
December 2nd 2020
- Frontline Therapy for mCSPC
December 2nd 2020
- AR-Targeted Therapy for mCSPC: Adverse Events
December 2nd 2020
- mCSPC: Incorporating Newer Therapies Into Practice
December 2nd 2020
- The TITAN Trial in mCSPC
December 2nd 2020
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5